Induced human pluripotent stem cells and advanced therapies: Future perspectives for the treatment of haemophilia?

Thrombosis Research

Volumn 128, Issue 1, 2011, Pages 8-13

  Liras, A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Advanced therapies; Cell therapy; Haemophilia; In vitro reprogramming; Induced pluripotent stem cells; iPSCs

Indexed keywords

ADENOVIRUS VECTOR; KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR SOX2;

ADENOVIRUS; CELL SURVIVAL; EPSTEIN BARR VIRUS; GENE THERAPY; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

ADULT; ANIMALS; CELL DIFFERENTIATION; GENE THERAPY; HEMOPHILIA A; HUMANS; INDUCED PLURIPOTENT STEM CELLS;

EID: 79958035838     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.01.010     Document Type: Review

References (60)

1. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007;1:39-49. (Pubitemid 46865811)
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76. (Pubitemid 44233629)
3. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-20.
4. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324:797-801.
5. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451:141-6.
6. Okita K, Hong H, Takahashi K, et al. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 2010;5:418-28.
7. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458:771-5.
8. Woltjen K, Michael IP, Mohseni P, et al. PiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-70.
9. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-4.
10. Lin T, Ambasudhan R, Yuan X, et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009;6:805-8.
11. Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA 2008;105:2883-8. (Pubitemid 351723638)
12. Alternative sources of human pluripotent stem cells. . Available atWhite paper: The President's Council on Bioethics. Washington, D.C; 2005 http://bioethics.georgetown.edu/pcbe/reports/white-paper/alternative-sources- white-paper.pdf. (last accessed on 23 January 2011).
13. 2008 Amendments to the National Academies' guidelines for human embryonic stem cell research. . Available atNational Research Council and Institute of Medicine. National Academy Press; 2008 http://www.nap.edu/openbook.php?record- id=12260&page=1. (last accessed on 23 January 2011).
14. Mayshar Y, Ben-David U, Lavon N, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010;7:521-31.
15. Rolletschek A, Wobus AM. Induced human pluripotent stem cells: promises and open questions. Biol Chem 2009;390:845-9.
16. Amabile G, Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol Med 2009;15:59-68.
17. Hochedlinger K, Plath K. Epigenetic reprogramming and induced pluripotency. Development 2009;136:509-23.
18. Tateishi K, He J, Taranova O, et al. Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem 2008;283:31601-7.
19. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-21.
20. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008;134:877-86.
21. Ebert AD, Yu J, Rose FF, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-80.
22. Caspi O, Itzhaki I, Arbel G, et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev 2009;18:161-72.
23. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008;105:5856-61. (Pubitemid 351758462)
24. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPSCs cells generated from autologous skin. Science 2007;318:1920-3.
25. Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008;118:507-17.
26. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104:e30-41.
27. Mason C, Manzotti E. Induced pluripotent stem cells: an emerging technology platform and the Gartner hype cycle. Regen Med 2009;4:329-31.
28. Nelson TJ, Terzic A. Induced pluripotent stem cells: reprogrammed without a trace. Regen Med 2009;4:333-55.
29. Nichols TC, Dillow AM, Franck HW, et al. Protein replacement therapy and gene transfer in canine models of haemophilia A, haemophilia B, von willebrand disease, and factor VII deficiency. ILAR J 2009;50:144-67.
30. Nienhuis AW. Development of gene therapy for blood disorders. Blood 2009;111:4431-44.
31. Liras A. Gene therapy for haemophilia: The end of a "royal pathology" in the third millennium? Haemophilia 2001;7:441-5.
32. Liras A, Olmedillas S. Gene therapy for haemophilia...yes, but...with non-viral vectors? Haemophilia 2009;15:811-6.
33. Viiala NO, Larsen SR, Rasko JE. Gene therapy for hemophilia: clinical trials and technical tribulations. Semin Thromb Hemost 2009;35:81-92.
34. Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007;110:4144-52. (Pubitemid 351377775)
35. Jeon HJ, Oh TK, Kim OH, et al. Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector. Yonsei Med J 2010;51:52-7.
36. Wang L, Herzog RW. AAV-mediated gene transfer for treatment of hemophilia. Curr Gene Ther 2005;5:349-60. (Pubitemid 40895019)
37. Arruda VR, Stedman HH, Haurigot V, et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 2010;115:4678-88.
38. Lu H, Chen L, Wang J, et al. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum Gene Ther 2008;19:648-54. (Pubitemid 351913523)
39. Jayandharan GR, Zhong L, Sack BK, et al. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Hum Gene Ther 2010;21:271-83.
40. Haurigot V, Mingozzi F, Buchlis G, et al. Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs. Mol Ther 2010;18:1318-29.
41. Greene TK, Wang C, Hirsch JD, et al. In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood 2010;116:6114-22.
42. Shi Q, Wilcox DA, Fahs SA, et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007;5:352-61. (Pubitemid 46139461)
43. Zhang G, Shi Q, Fahs SA, et al. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. Blood 2010;116:1235-43.
44. Xu L, Nichols TC, Sarkar R, et al. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci USA 2005;102:6080-5. (Pubitemid 40594258)
45. Xu L, Mei M, Haskins ME, et al. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thromb Res 2007;120:269-80. (Pubitemid 46754415)
46. Schmidt M, Hacein-Bey-Abina S, Wissler M, et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood 2005;105:2699-706. (Pubitemid 40446259)
47. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency. N Engl J Med 2010;363:355-64.
48. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-58.
49. Ide LM, Iwakoshi NN, Gangadharan B, et al. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A. J Gene Med 2010;12:333-44.
50. Sivalingam J, Krishnan S, Ng WH, et al. Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells. Mol Ther 2010;18:1346-56.
51. Aronovich A, Tchorsh D, Katchman H, et al. Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation. Proc Natl Acad Sci USA 2006;103:19075-80. (Pubitemid 350002830)
52. Follenzi A, Benten D, Novikoff P, et al. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008;118:935-45. (Pubitemid 351364601)
53. Xu D, Alipio Z, Fink LM, et al. Phenotypic correction of murine hemophilia A using an iPSCs cell-based therapy. Proc Natl Acad Sci USA 2009;106:808-13.
54. Yadav N, Kanjirakkuzhiyil S, Kumar S, et al. The therapeutic effect of bone marrow-derived liver cells in the phenotypic correction of murine hemophilia A. Blood 2009;114:4552-61.
55. Nelson TJ, Martinez-Fernandez A, Yamada S, et al. Induced pluripotent stem cells: advances to applications. Stem Cells Cloning Adv Appl 2010;3:29-37.
56. Zhou H, Ding S. Evolution of induced pluripotent stem cell technology. Curr Opin Hematol 2010;17:276-80.
57. Lengner CJ. iPS cell technology in regenerative medicine. Ann NY Acad Sci 2010;1192:38-44.
58. Phillips BW, Crook JM. Pluripotent human stem cells: A novel tool in drug discovery. BioDrugs 2010;24:99-108.
59. Lapillonne H, Kobari L, Mazurier C, et al. Red blood cells generation from human induced pluripotent stem cells: perspectives for transfusion medicine. Haematologica 2010;95:1651-9.
60. Wong GK, Chiu AT. Gene therapy, gene targeting and induced pluripotent stemcells: Applications in monogenic disease treatment. Biotechnol Adv 2011;29:1-10.